An early diagnosis for lung cancer can mean a cure.
Develop sensitive and
specific blood test to
Lung Cancer Proteomics has spent 13 years developing a simple blood test that can detect early stage Non-Small Cell Lung Cancer (NSCLC) with high sensitivity and specificity.
Commit to a
We focus on evaluating protein biomarkers in conjunction with proprietary algorithms and patient demographic information to provide a risk assessment for early stage lung cancer.
Simplify and improve diagnostic tools leading to
In 2016, we completed the validation of the Lung Cancer Detection Test 1 (LCDT1). The LCDT1 is a simple blood test that detects Stage 1 lung cancer with high accuracy.
Our mission is to develop sensitive and specific blood tests to detect high mortality cancers early.
We strictly adhere to a data driven approach and use rigorous scientific processes. We strive to innovate, simplify, and improve early diagnostic tools which lead to a better quality of life for cancer patients and increase survival.
Lung Cancer Proteomics, LLC
105 Washington Street
Michigan City, IN 46360
Bay Area Laboratory
6541-B Via Del Oro
San Jose, CA 95119